AZN - AstraZeneca PLC
| Previous close | 54.10 |
| Open | 53.50 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1400 |
| Day's range | 53.43 - 54.28 |
| 52-week range | 36.15 - 57.44 |
| Volume | 3,650,674 |
| Avg. volume | 4,984,424 |
| Market cap | 140.112B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 92.43 |
| EPS (TTM) | 0.58 |
| Earnings date | N/A |
| Forward dividend & yield | 1.40 (2.59%) |
| Ex-dividend date | 27 Feb 2020 |
| 1y target est | 55.27 |
- Stockopedia
Analysts optimistic on Astrazeneca outlook
The Astrazeneca (LON:AZN) share price has risen by 2.76% over the past month and it’s currently trading at 8543. For investors considering whether to buy, hold...
- Fool.co.uk
The AstraZeneca (AZN) share price is high, is this FTSE 100 star a recession-beating stock?
The AstraZeneca (AZN) share price is up 42% since the March market crash but is this FTSE 100 (INDEXFTSE:UKX) riser overvalued? The post The AstraZeneca (AZN) share price is high, is this FTSE 100 star a recession-beating stock? appeared first on The Motley Fool UK.
- Reuters
Make a vaccine? I'm trying to teach my kids the alphabet
British drugmaker AstraZeneca had spent years preparing for a pandemic, but when the moment finally came it was caught cold on a crucial front: stressed parents working from home struggled to focus. The move by Britain's biggest drugmaker, and similar efforts by companies the world over to host everything from magic classes to yoga for children, shows the lengths businesses are going to to help staff work through the coronavirus crisis. "It was quite apparent that it was going to be really challenging for those with small kids and with two parents working," AstraZeneca's HR chief Fiona Cicconi told Reuters.
- Zacks
BMY or AZN: Which Is the Better Value Stock Right Now?
BMY vs. AZN: Which Stock Is the Better Value Option?
- Zacks
FDA Issues Guidance for Coronavirus Vaccine Developers
Around a dozen companies are developing a vaccine for the deadly coronavirus disease.
- Reuters
COVID-19 vaccine candidates with early human-trial data
Moderna Inc said in May that its vaccine candidate, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, though doubts remain over whether the data is predictive of real-life success. China's military on Monday was cleared to use the COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy. U.S. company Inovio Pharmaceuticals said on Tuesday its experimental coronavirus vaccine induced immune responses in healthy volunteers and was shown to be safe in an early-stage trial.
- Motley Fool
What Does AstraZeneca's COVID-19 Vaccine Push Mean for Moderna?
Moderna (NASDAQ: MRNA) was the first to begin human trials of a coronavirus vaccine back in March. The clinical-stage biotech company delighted investors when it announced encouraging data from phase 1, quickly moved on to phase 2, and promised to start phase 3 in July. While Moderna remains a front-runner in the race to develop a vaccine for COVID-19, the illness caused by the novel coronavirus, the company has fallen into the shadow of big pharma.
- Reuters
Brazil signs agreement to produce AstraZeneca's experimental COVID-19 vaccine
Brazil announced on Saturday that it had signed a $127 million agreement to start producing locally an experimental vaccine developed by AstraZeneca that has shown promise to fight the COVID-19 pandemic. The AstraZeneca vaccine is considered the world's leading candidate and most advanced in terms of development to obtain licensure and become an official vaccine against the disease, according to the World Health Organization. Elcio Franco, Brazil's No.2 public health official, said in a press conference that the country will initially produce some 30 million doses of the vaccine, half by December and half by January of next year.
- Zacks
Moderna Collaborates With Catalent for Coronavirus Vaccine
Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.
- Reuters
AstraZeneca, Moderna ahead in COVID-19 vaccine race - WHO
AstraZeneca's experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday. The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford. This week, AstraZeneca signed its tenth supply-and-manufacturing deal.
- Reuters
Daiichi Sankyo in talks with AstraZeneca on virus vaccine supply in Japan
Daiichi Sankyo Co is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca Plc and the University of Oxford for use in Japan. The discussion follows a flurry of supply deals signed by the British drug maker for its experimental COVID-19 vaccine as it ramps up efforts for wider trials of the potential treatment. Daiichi Sankyo said in a statement on Friday that one of its subsidiaries would receive undiluted solution of the vaccine and then carry out formulation procedures, packaging, and storage in Japan.
- Business Wire
PT010 Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial
Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy PT010 (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
- Zacks
Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
- Reuters
AstraZeneca taps Scottish firm for 10th COVID-19 vaccine supply deal
Symbiosis Pharmaceutical said on Wednesday it agreed to make and supply an unspecified number of units of the vaccine, AZD1222, for AstraZeneca to use in clinical trials. The companies did not provide any financial terms of the deal. AstraZeneca Chief Executive Officer Pascal Soriot last month warned that the company was running out of time to effectively test the vaccine as the number of cases decline in Europe.
- Reuters
AstraZeneca taps Scottish firm for tenth COVID-19 vaccine supply deal
Symbiosis Pharmaceutical said on Wednesday it agreed to make and supply an unspecified number of units of the vaccine, AZD1222, for AstraZeneca to use in clinical trials. The companies did not provide any financial terms of the deal. AstraZeneca Chief Executive Officer Pascal Soriot last month warned that the company was running out of time to effectively test the vaccine as the number of cases decline in Europe.
- Zacks
Pfizer Begins Four Phase III Studies on Vaccine Candidates
Pfizer (PFE) begins four phase III studies on vaccine candidates. EMA validates its label expansion application for Bavencio in first-line bladder cancer.
- Reuters
Pig trial of AstraZeneca's COVID-19 vaccine shows promise with two shots
A trial in pigs of AstraZeneca's experimental COVID-19 vaccine has found that two doses of the shot produced a greater antibody response than a single dose. Research released by Britain's Pirbright Institute on Tuesday found that giving an initial prime dose followed by a booster dose of the vaccine elicited a stronger immune response than a single dose. "The researchers saw a marked increase in neutralising antibodies, which bind to the virus in a way that blocks infection," the Pirbright team said in a statement.
- Zacks
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb
- Zacks
Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs
FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.
- Zacks
Buy These 4 Big Drugmakers to Keep Coronavirus Woes at Bay
Here we highlight four large drugmakers that can prove to be safe bets amid the coronavirus crisis.
- Fool.co.uk
I think the AstraZeneca share price could be the best UK buy right now
The AstraZeneca share price has doubled in the past five years. Here's why I think the next five years could be even more profitable.The post I think the AstraZeneca share price could be the best UK buy right now appeared first on The Motley Fool UK.
- Reuters
Exclusive: EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal - sources
The European Commission is in advanced talks with pharmaceuticals giant Johnson & Johnson to reserve or make an up-front purchase of its COVID-19 vaccine under development, two officials familiar with the talks told Reuters. The move would be the first arranged by the European Union executive since it was mandated by the 27 EU national governments to use an emergency fund of more than 2 billion euros ($2.3 billion) to strike deals with up to six vaccine producers. The Commission's deal with U.S. company Johnson & Johnson is "in the pipeline", a top health official from an EU member state said, asking to remain anonymous because because the talks were confidential discussions about vaccines between the EU executive and EU governments.
- Zacks
Lilly Gains as Verzenio Meets Early Breast Cancer Study Goal
Lilly's (LLY) phase III study on Verzenio in HR+, HER2- early breast cancer met its primary endpoint of invasive disease-free survival.
- Stockopedia
Astrazeneca hits 52w high – but will it continue?
It's a good time to be a shareholder in Astrazeneca (LON:AZN): as the share approaches its 52-week high, holders may be wondering whether to sell and take the...
